Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
World J Pediatr ; 19(6): 557-567, 2023 Jun.
Article in English | MEDLINE | ID: mdl-35951258

ABSTRACT

BACKGROUND: Home oxygen therapy (HOT) is indicated upon discharge in some preterm infants with severe bronchopulmonary dysplasia (BPD). There is a lack of evidence-based consensus on the indication for HOT among these infants. Because wide variation in the institutional use of HOT exists, little is known about the role of regional social-economic level in the wide variation of HOT. METHODS: This was a secondary analysis of Chinese Neonatal Network (CHNN) data from January 1, 2019 to December 31, 2019. Infants at gestational ages < 32 weeks, with a birth weight < 1500 g, and with moderate or severe BPD who survived to discharge from tertiary hospitals located in 25 provinces were included in this study. Infants with major congenital anomalies and those who were discharged against medical advice were excluded. RESULTS: Of 1768 preterm infants with BPD, 474 infants (26.8%) were discharged to home with oxygen. The proportion of HOT use in participating member hospitals varied from 0 to 89%, with five of 52 hospitals' observing proportions of HOT use that were significantly greater than expected, with 14 hospitals with observing proportions significantly less than expected, and with 33 hospitals with appropriate proportions. We noted a negative correlation between different performance groups of HOT and median GDP per capita (P = 0.04). CONCLUSIONS: The use of HOT varied across China and was negatively correlated with the levels of provincial economic levels. A local HOT guideline is needed to address the wide variation in HOT use with respect to different regional economic levels in countries like China.


Subject(s)
Bronchopulmonary Dysplasia , Infant, Premature , Infant , Infant, Newborn , Humans , Bronchopulmonary Dysplasia/therapy , Bronchopulmonary Dysplasia/complications , Gestational Age , Oxygen/therapeutic use , China , Cohort Studies , Infant, Very Low Birth Weight
2.
Toxicon ; 218: 88-98, 2022 Oct 30.
Article in English | MEDLINE | ID: mdl-36113685

ABSTRACT

Antimicrobial peptides (AMPs) have started to garner more interest as novel antimicrobial agents. The scorpion venom peptide ctry2459 was modified to CT-K3K7 by lysine substitutions at the 3rd and 7th positions to increase the cationic properties. We discovered that the modified peptides CT-K3K7 had improved antibacterial activity, higher thermal stability, as well as lower hemolytic activity. It can kill S. aureus and P. aeruginosa rapidly, and reduce the production of biofilm and live bacterial residues in biofilm in vitro. CT-K3K7 has also been demonstrated to decrease bacterial counts, abscess area, and inflammatory cell infiltration in the mouse subcutaneous abscess models that were duplicated by S. aureus and P. aeruginosa. CT-K3K7 has difficulty in inducing S. aureus and P. aeruginosa to develop drug resistance, which may be related to the bactericidal properties. CT-K3K7 increases cationic properties by lysine substitutions can increase the electrostatic force between the peptides and the bacterial surface, which can lead to an increase in bacterial membrane permeability and DNA binding. In conclusion, the modified peptide CT-K3K7 enhances the antimicrobial activity and can be a novel antimicrobial agent candidate for the treatment of infections by S. aureus and P. aeruginosa.


Subject(s)
Anti-Infective Agents , Scorpion Venoms , Abscess , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Antimicrobial Cationic Peptides/chemistry , Antimicrobial Cationic Peptides/pharmacology , Bacteria , DNA , Lysine/chemistry , Mice , Microbial Sensitivity Tests , Pseudomonas aeruginosa , Scorpions , Staphylococcus aureus , Tomography, X-Ray Computed
3.
Macromol Rapid Commun ; 43(21): e2200480, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35946394

ABSTRACT

Ionogels have attracted intensive attentions as promising flexible conductive materials. However, simultaneous integration of excellent mechanical properties, high conductivity, outstanding self-healing ability, and strong adhesiveness is still challenging. Here, an ingenious composition design is proposed to address this long-standing challenge of ionogels. High-performance PEI/PAA/CMC ionogels, consist of a loosely cross-linked poly(acrylic acid) (PAA) network, dynamically cross-linked network based on polycationic polyethyleneimine (PEI) and polyanionic PAA, and carboxymethyl cellulose (CMC) reinforcing filler, are formed in a deep eutectic solvent (DES) composed of choline chloride and urea. Benefiting from the loose PAA network and dynamic noncovalent interactions, ionogels with both highly enhanced mechanical robustness and excellent conductivity are obtained at high loading of DES, overcoming the strength-ductility/conductivity trade-off dilemma. By adjusting PEI/PAA mass ratio, the tensile strength and strain of PEI/PAA/CMC ionogels are effectively controlled in a wide range of 0.15-7.9 MPa and 232-1161%, respectively, while maintaining the desirable conductivity of ≈10-4 S cm-1 . Besides, healed tensile strength over 2.1 MPa and adhesion strength up to 0.2 MPa are achieved for the PEI0.06 /PAA0.25 /CMC0.01 ionogel. The delicate design strategy provides a feasible approach to prepare ionogels with outstanding comprehensive performance, which have potential for applications in flexible electronics.

4.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 34(5): 522-5, 2014 May.
Article in Chinese | MEDLINE | ID: mdl-24941836

ABSTRACT

OBJECTIVE: To observe the effect of three Chinese medical formulae (Zhifei Mixture I , Zhfei Mixture II, and Zhifei Mixture II) on main and secondary symptoms and signs of children with Totally 70 mycoplasma pneumonia in treating three types of children mycoplasma pneumonia. METHODS: children with mycoplasma pneumonia were assigned to the control group (38 cases) and the treatment group (32 case). All patients were intravenously injected with Azithromycin and took Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution. Those in the treatment group additionally took Zhifei Mixture I , Zhfei Mixture II, and Zhifei Mixture Ill by syndrome typing. Their main and secondary symptoms and signs were observed before and after treatment (main symptoms and signs covered fever, cough, abundant sputum, short breath, and anoxia; secondary symptoms and signs covered aversion to cold, heart rate, facial complexion, spirit, appetite, and sweating). RESULTS: Seven patients were lost in this study. Compared with before treatment in the same group, scores for main and secondary symptoms and signs decreased in the treatment group (P <0.01). The therapeutic effect on fever and cough was obviously better in the control group (P <0.01). The main and secondary symptoms and signs were more obviously improved in the treatment group than in the control group (P <0.01). Commpared with the control group, scores for main and secondary symptoms and signs decreased more in the treatment group (P <0.01). Patients' main and secondary symptoms and signs were more obviously improved (P <0.05). CONCLUSIONS: Zhifei Mixture combined Western drugs could significantly improve main and secondary symptoms and signs of mycoplasma pneumonia children patients. Its efficacy was superior to that of using Western medicine alone.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Pneumonia, Mycoplasma/drug therapy , Ambroxol/administration & dosage , Ambroxol/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Azithromycin/administration & dosage , Azithromycin/therapeutic use , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/therapeutic use , Child , Clenbuterol/administration & dosage , Clenbuterol/therapeutic use , Expectorants/administration & dosage , Expectorants/therapeutic use , Fever , Humans , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...